Latest Disease-modifying antirheumatic drug Stories
Hollis-Eden Pharmaceuticals has started a Phase I/II open label dose ranging clinical trial with its investigational oral drug candidate Triolex in patients diagnosed with rheumatoid arthritis and receiving a stable dose of methotrexate, the current standard of care in rheumatoid arthritis.
Roche has announced that the arthritis advisory committee of the FDA has recommended approval of Actemra, a novel interleukin-6 receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis.
NUTLEY, N.J., July 29 /PRNewswire/ -- Roche today announced that the Arthritis Advisory Committee of the U.S.
The European marketing authorisation application for Cimzia(R) has been filed. Subject to approval, Cimzia(R) will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
Lux Biosciences today announced the completion of enrollment for the landmark LUMINATE (Luveniq Uveitis Multicenter Investigation of a New Approach to TrEatment) pivotal clinical trial program, which is investigating the use of LUVENIQ(TM) (voclosporin; previously designated LX211) as a corticosteroid-sparing agent for the treatment of patients with non-infectious uveitis.
In patients with rheumatoid arthritis, use of disease-modifying antirheumatic drugs, or DMARDs, seems to lower the increased risk of cardiovascular disease associated with rheumatoid arthritis, research suggests.
NEW YORK (Reuters Health) - Even if an initial course of methotrexate for the treatment of rheumatoid arthritis (RA) gives disappointing results, persistence may pay off. A second course may be more successful, researchers report.
By Amy Norton NEW YORK (Reuters Health) - The medical costs of employees with rheumatoid arthritis are among the highest of any chronic health condition, new research suggests. In a study of nine large U.S.
Adults with rheumatoid arthritis (RA) can safely receive the flu vaccine each year as recommended, although their response to the vaccine may be somewhat lower than in healthy individuals, research hints.
ZURICH (Reuters) - Roche said on Thursday its Actemra drug, developed by Japanese partner Chugai, was better than current standard treatments in preventing the progression of joint destruction in patients with rheumatoid arthritis.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.